Vaccine based on membrane bound proteins and process for making them
AssigneeGenentech, Inc.
InventorsPhillip W. Berman, Laurence A. Lasky
Life of this patent
Estimating the term…
Abstract
Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of glycoproteins of the organism, that have been prepared via recombinant means, and preferably C-truncated versions thereof. These glycoproteins when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.
Claims10
A vaccine effective against herpes simplex virus type 1 or type 2 pathogen comprising a membrane-bound polypeptide having exposed antigenic determinants that raise neutralizing antibodies against in vivo challenge by said pathogen, said polypeptide being functionally associated with a membrane of a recombinant, stable, mammalian continuous cell line used in its production, said polypeptide comprising a gD glycoprotein of herpes simplex virus type 1 or type 2.
A vaccine effective against herpes simplex virus type 1 or type 2 pathogen comprising a membrane-free polypeptide having exposed antigenic determinants that raise neutralizing antibodies against in vivo challenge by said pathogen, said polypeptide produced in a recombinant, stable, mammalian continuous cell line, said polypeptide comprising a full-length or truncated gD glycoprotein of herpes simplex virus type 1 or type 2.
A method according to claim 5 or 22 wherein the cell line is a CHO cell line deficient in the production of dhfr and the vector contains a dhfr selectible marker.
A method of making a vaccine useful against in vivo challenge with herpes simplex virus type 1 or type 2, comprising incorporating a truncated gD polypeptide from herpes simplex virus type 1 or type 2 into vaccine form.
Dependencies are inferred from the claim text.